REFERENCES
- Crist WM, Kun LE. Common solid tumors of childhood. N Engl J Med. 1991;324:461–471.
- Grundy P, Breslow N, Green DM, et al. Prognostic factors for children with recurrent Wilms’ tumor: results from the Second and Third National Wilms’ Tumor Study. J Clin Oncol. 1989;7:638–647.
- Green DM, Breslow NE, Beckwith JB, et al. Treatment with nephrectomy only for small, stage I/favorable histology Wilms’ tumor: a report from the National Wilms’ Tumor Study Group. J Clin Oncol. 2001;19:3719–3724.
- Perlman EJ1, Grundy PE, Anderson JR, et al. WT1 mutation and 11P15 loss of heterozygosity predict relapse in very low-risk Wilms tumors treated with surgery alone: a Children's Oncology Group study. J Clin Oncol. 2011;29:698–703.
- De Kraker J1, Graf N, van Tinteren H, et al. Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms’ tumour (SIOP 93-01 trial): a randomised controlled trial. Lancet. 2004;36:1229–1235.
- Dome JS, Coppes MJ. Recent advances in Wilms tumor genetics. Curr Opin Pediatr. 2002;14:5–11.
- Grundy RG, Pritchard J, Scambler P, Cowell JK. Loss of heterozygosity on chromosome 16 in sporadic Wilms’ tumour. Br J Cancer. 1998;78:1181–1187.
- Grundy PE, Telzerow PE, Breslow N, et al. Loss of heterozygosity for chromosomes 16q and 1p in Wilms’ tumors predicts an adverse outcome. Cancer Res. 1994;54:2331–2333.
- Grundy PE, Breslow NE, Li S, et al. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol. 2005;23:7312–7321.
- Beckwith JB. National Wilms Tumor Study: an update for pathologists. Pediatr Dev Pathol. 1998;1:79–84.
- Green DM, Breslow NE, Beckwith JB, et al. Effect of duration of treatment on treatment outcome and cost of treatment for Wilms’ tumor: a report from the National Wilms’ Tumor Study Group. J Clin Oncol. 1998;16:3744–3751.
- Spreafico F, Gamba B, Mariani L, et al. Loss of heterozygosity analysis at different chromosome regions in Wilms tumor confirms 1p allelic loss as a marker of worse prognosis: a study from the Italian Association of Pediatric Hematology and Oncology. J Urol. 2013;189:260–266.
- Messahel B, Williams R, Ridolfi A, et al. Allele loss at 16q defines poorer prognosis Wilms tumour irrespective of treatment approach in the UKW1–3 clinical trials: a Children's Cancer and Leukaemia Group (CCLG) study. Eur J Cancer. 2009;45:819–826.
- Pritchard-Jones K, Moroz V, Vujanić G, et al. Treatment and outcome of Wilms’ tumour patients: an analysis of all cases registered in the UKW3 trial. Ann Oncol. 2012;23:2457–2463.
- Yankelevich, M, Dolgopolov, I, Ravshanova R, Kamaeva O, Lebedev V, Izshogin D, Socolova I, Siegel S E, and Mentkevich G. Efficacy and toxicity of ifosfamide/cyclophosphamide, carboplatin, and etoposide (ICE/CCE) chemotherapy with or without GM-CSF in relapsed or refractory Wilms’ tumor: a single institution study. Int J Pediatr Hematol Oncol. 1999;6:331–338.